Gülşah Geli̇şİgÜzel
Research Subjects
Gülşah Geli̇şİgÜzel has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Kader Arslan
ANKARA EĞİTİM VE ARAŞTIRMA HASTANESİ, ENFEKSİYON HASTALIKLARI VE KLİNİK MİKROBİYOLOJİ
3 shared publications - Salih Cesur
ANKARA EĞİTİM VE ARAŞTIRMA HASTANESİ, ENFEKSİYON HASTALIKLARI VE KLİNİK MİKROBİYOLOJİ
3 shared publications - Sami Kinikli
Sağlık Bilimleri Üniversitesi, Ankara Eğitim ve Araştırma Hastanesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Kliniği, Ankara
3 shared publications - Şerife Altun Demircan
Sağlık Bilimleri Üniversitesi Ankara Eğitim ve Araştırma Hastanesi
3 shared publications - Esra Kaya Kiliç
Sağlık Bilimleri Üniversitesi, Ankara Eğitim ve Araştırma Hastanesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Kliniği, Ankara
2 shared publications - Gunay Tuncer Ertem
ANKARA EĞİTİM VE ARAŞTIRMA HASTANESİ, ENFEKSİYON HASTALIKLARI VE KLİNİK MİKROBİYOLOJİ
2 shared publications
Latest Publications
- Open Access
- 20 February 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (2) , 229
Prospective Evaluation of ESBL Risk Factors and Appropriateness of Empirical Therapy in Hospitalized Patients with Community-Onset Pyelonephritis
Background/Objectives: The rising prevalence of extended-spectrum beta-lactamase (ESBL)-producing pathogens has emerged as a significant challenge in the treatment of pyelonephritis. This study aims to determine the frequency of ESBL-producing agents in hospitalized patients with pyelonephritis, identify associated risk factors, and assess the appropriateness of empirical antimicrobial therapy. Methods: This prospective study included patients hospitalized with pyelonephritis in the Infectious Diseases Clinic of Ankara Training and Research Hospital between 1 October 2022 and 29 February 2024. Demographic features, comorbidities, urinary system pathologies, history of urinary tract interventions, hospitalization more than one month prior, antibiotic use within the previous three months, and prior urinary tract infections were compared between patients infected with ESBL-producing and non-ESBL-producing organisms. Antimicrobial susceptibility profiles and the appropriateness of empirical treatments were evaluated. Statistical analyses were performed using SPSS version 25.0, with p < 0.05 considered statistically significant. Results: Escherichia coli (n = 142) and Klebsiella spp. (n = 43) were isolated in 180 of 204 patients. ESBL positivity was detected in 95 patients (52.7%). In the multivariate logistic regression analysis, male sex (p = 0.038) and hospitalization more than one month prior (p = 0.016) were identified as independent risk factors for ESBL positivity, while prior antibiotic use in the last three months showed a borderline association (p = 0.055) and did not reach statistical significance. ESBL production was not associated with prolonged hospitalization; however, bacteremia significantly increased length of stay (p < 0.001). Antimicrobial susceptibility rates were markedly lower in the ESBL-positive group. The appropriateness of empirical therapy was also significantly reduced, with piperacillin–tazobactam being the most frequently inappropriate agent due to high resistance rates and unnecessary broad-spectrum use. Conclusions: ESBL-producing pathogens were highly prevalent among hospitalized patients with pyelonephritis. The low appropriateness of empirical therapy in ESBL-positive cases underscores the need for careful evaluation of ESBL risk factors prior to treatment initiation, as ESBL rates may approach 50%.
- 20 February 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (2) , 229
Open AccessProspective Evaluation of ESBL Risk Factors and Appropriateness of Empirical Therapy in Hospitalized Patients with Community-Onset Pyelonephritis
Background/Objectives: The rising prevalence of extended-spectrum beta-lactamase (ESBL)-producing pathogens has emerged as a significant challenge in the treatment of pyelonephritis. This study aims to determine the frequency of ESBL-producing agents in hospitalized patients with pyelonephritis, identify associated risk factors, and assess the appropriateness of empirical antimicrobial therapy. Methods: This prospective study included patients hospitalized with pyelonephritis in the Infectious Diseases Clinic of Ankara Training and Research Hospital between 1 October 2022 and 29 February 2024. Demographic features, comorbidities, urinary system pathologies, history of urinary tract interventions, hospitalization more than one month prior, antibiotic use within the previous three months, and prior urinary tract infections were compared between patients infected with ESBL-producing and non-ESBL-producing organisms. Antimicrobial susceptibility profiles and the appropriateness of empirical treatments were evaluated. Statistical analyses were performed using SPSS version 25.0, with p < 0.05 considered statistically significant. Results: Escherichia coli (n = 142) and Klebsiella spp. (n = 43) were isolated in 180 of 204 patients. ESBL positivity was detected in 95 patients (52.7%). In the multivariate logistic regression analysis, male sex (p = 0.038) and hospitalization more than one month prior (p = 0.016) were identified as independent risk factors for ESBL positivity, while prior antibiotic use in the last three months showed a borderline association (p = 0.055) and did not reach statistical significance. ESBL production was not associated with prolonged hospitalization; however, bacteremia significantly increased length of stay (p < 0.001). Antimicrobial susceptibility rates were markedly lower in the ESBL-positive group. The appropriateness of empirical therapy was also significantly reduced, with piperacillin–tazobactam being the most frequently inappropriate agent due to high resistance rates and unnecessary broad-spectrum use. Conclusions: ESBL-producing pathogens were highly prevalent among hospitalized patients with pyelonephritis. The low appropriateness of empirical therapy in ESBL-positive cases underscores the need for careful evaluation of ESBL risk factors prior to treatment initiation, as ESBL rates may approach 50%.
- Open Access
- 15 January 2026
- Published by MDPI AG in Preprints.org
Prospective Evaluation of ESBL Risk Factors and Appropriateness of Empirical Therapy in Hospitalized Patients with Community-Acquired Pyelonephritis
Background/Objectives: The rising prevalence of extended-spectrum beta-lactamase (ESBL)–producing pathogens has emerged as a significant challenge in the treatment of pyelonephritis. This study aimed to determine the frequency of ESBL-producing agents in hospitalized patients with pyelonephritis, identify associated risk factors, and assess the appropriateness of empirical antimicrobial therapy. Methods: This prospective study included patients hospitalized with pyelonephritis in the Infectious Diseases Clinic of Ankara Training and Research Hospital between October 1, 2022, and February 29, 2024. Demographic features, comorbidities, urinary system pathologies, history of urinary tract interventions, recent hospitalization, antibiotic use within the previous three months, and prior urinary tract infections were compared between patients infected with ESBL-producing and non-ESBL-producing organisms. Antimicrobial susceptibility pro-files and the appropriateness of empirical treatments were evaluated. Statistical analyses were performed using SPSS version 25.0, with p< 0.05 considered statistically significant. Results: Escherichia coli (n=142) and Klebsiella spp. (n=43) were isolated in 180 of 204 patients. ESBL positivity was detected in 95 patients (52.7%). Male sex (p=0.007), history of urinary intervention (p=0.019), hospitalization within the previous month (p< 0.001), and antibiotic use in the last three months (p=0.002) were identified as significant risk factors for ESBL positivity. ESBL production was not associated with prolonged hospitalization; however, bacteremia significantly increased length of stay (p< 0.001). Antimicrobial susceptibility rates were markedly lower in the ESBL-positive group. The appropriateness of empirical therapy was also significantly reduced, with piperacillin–tazobactam being the most frequently inappropriate agent due to high resistance rates and unnecessary broad-spectrum use. Conclusions: ESBL-producing pathogens were highly prevalent among hospitalized patients with pyelonephritis. The low appropriateness of empirical therapy in ESBL-positive cases underscores the need for careful evaluation of ESBL risk factors prior to treatment initiation, as ESBL rates may approach 50%.
- 15 January 2026
- Published by MDPI AG in Preprints.org
Open AccessProspective Evaluation of ESBL Risk Factors and Appropriateness of Empirical Therapy in Hospitalized Patients with Community-Acquired Pyelonephritis
Background/Objectives: The rising prevalence of extended-spectrum beta-lactamase (ESBL)–producing pathogens has emerged as a significant challenge in the treatment of pyelonephritis. This study aimed to determine the frequency of ESBL-producing agents in hospitalized patients with pyelonephritis, identify associated risk factors, and assess the appropriateness of empirical antimicrobial therapy. Methods: This prospective study included patients hospitalized with pyelonephritis in the Infectious Diseases Clinic of Ankara Training and Research Hospital between October 1, 2022, and February 29, 2024. Demographic features, comorbidities, urinary system pathologies, history of urinary tract interventions, recent hospitalization, antibiotic use within the previous three months, and prior urinary tract infections were compared between patients infected with ESBL-producing and non-ESBL-producing organisms. Antimicrobial susceptibility pro-files and the appropriateness of empirical treatments were evaluated. Statistical analyses were performed using SPSS version 25.0, with p< 0.05 considered statistically significant. Results: Escherichia coli (n=142) and Klebsiella spp. (n=43) were isolated in 180 of 204 patients. ESBL positivity was detected in 95 patients (52.7%). Male sex (p=0.007), history of urinary intervention (p=0.019), hospitalization within the previous month (p< 0.001), and antibiotic use in the last three months (p=0.002) were identified as significant risk factors for ESBL positivity. ESBL production was not associated with prolonged hospitalization; however, bacteremia significantly increased length of stay (p< 0.001). Antimicrobial susceptibility rates were markedly lower in the ESBL-positive group. The appropriateness of empirical therapy was also significantly reduced, with piperacillin–tazobactam being the most frequently inappropriate agent due to high resistance rates and unnecessary broad-spectrum use. Conclusions: ESBL-producing pathogens were highly prevalent among hospitalized patients with pyelonephritis. The low appropriateness of empirical therapy in ESBL-positive cases underscores the need for careful evaluation of ESBL risk factors prior to treatment initiation, as ESBL rates may approach 50%.
- 5 June 2021
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 2 (2) , 58-61
Polimeraz zincir reaksiyonu ile tanısı konulan ve komplikasyonla seyreden bir pnömokok menenjiti olgusu
Bakteriyel menenjitlerin erken tanısı ve tedavisinde kültür sonuçları en erken 24-48 saatte çıktığından ötürü, klinik bulgularla birlikte BOS’da hücre sayımı, BOS’un biyokimyasal özellikleri ve BOS’un Gram boyama ile incelenmesi büyük önem taşımaktadır. Özellikle menenjitlerin infeksiyon acili olması nedeniyle kültür için BOS ve kan örneği alınmadan ampirik tedavinin erken başlandığı veya hastaların önceden antibiyotik tedavisi aldığı durumlarda kültürde etkenin saptanma olasılığı azalır veya ortadan kalkar. Bu gibi durumlarda BOS’un Gram boyaması, BOS’da bakteri antijenlerinin araştırılması yanı sıra son yıllarda polieraz zincir reaksiyonu ile de bakteri DNA’sı araştırılarak da tanıya gidilebilmektedir. Burada, menenjit ön tanısıyla BOS örneği alınmadan seftriakson tedavisi başlanan bu nedenle kültürde etkenin saptanmadığı, ancak; multipleks PZR yöntemiyle BOS’da Streptococcus pneumoniae (S.pneumoniae) pozitif saptanan 46 yaşında bir kadın hasta sunularak literatür gözden geçirildi. Olguda uygun antimikrobiyal tedaviye rağmen, pnömokok menenjiti komplikasyonu olarak superior sagittal sinüs ve bilateral transverslerde yaygın serebral trombüs gelişti.
- 5 June 2021
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 2 (2) , 58-61
Polimeraz zincir reaksiyonu ile tanısı konulan ve komplikasyonla seyreden bir pnömokok menenjiti olgusu
Bakteriyel menenjitlerin erken tanısı ve tedavisinde kültür sonuçları en erken 24-48 saatte çıktığından ötürü, klinik bulgularla birlikte BOS’da hücre sayımı, BOS’un biyokimyasal özellikleri ve BOS’un Gram boyama ile incelenmesi büyük önem taşımaktadır. Özellikle menenjitlerin infeksiyon acili olması nedeniyle kültür için BOS ve kan örneği alınmadan ampirik tedavinin erken başlandığı veya hastaların önceden antibiyotik tedavisi aldığı durumlarda kültürde etkenin saptanma olasılığı azalır veya ortadan kalkar. Bu gibi durumlarda BOS’un Gram boyaması, BOS’da bakteri antijenlerinin araştırılması yanı sıra son yıllarda polieraz zincir reaksiyonu ile de bakteri DNA’sı araştırılarak da tanıya gidilebilmektedir. Burada, menenjit ön tanısıyla BOS örneği alınmadan seftriakson tedavisi başlanan bu nedenle kültürde etkenin saptanmadığı, ancak; multipleks PZR yöntemiyle BOS’da Streptococcus pneumoniae (S.pneumoniae) pozitif saptanan 46 yaşında bir kadın hasta sunularak literatür gözden geçirildi. Olguda uygun antimikrobiyal tedaviye rağmen, pnömokok menenjiti komplikasyonu olarak superior sagittal sinüs ve bilateral transverslerde yaygın serebral trombüs gelişti.
- 23 March 2021
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 2 (1) , 25-27
İlk doz kolistin kullanımı sonrasında kolistine bağlı olarak nöropati gelişen bir olgu
Kateter enfeksiyonlarının en sık etkeni cilt florasında yer alan stafilokoklar ve diğer Gram-pozitif bakterilerdir. Citrobacter freundii çoğunlukla nozokomiyal enfeksiyon etkeni olup, nadiren kateterle ilişkili kan dolaşımı enfeksiyonuna neden olur. Bu yazıda, hemodiyalize giren 39 yaşında bir erkek hastada Citrobacter freundii’ye bağlı olarak gelişen kateterle kan dolaşımı enfeksiyonu gelişen bir olgu sunuldu. Hastanın periferik kan ve kateter içinden alınan kan örneklerinde Citrobacter freundii üredi. Hastaya 10 gün süreyle seftriakson tedavisi uygulandı, tedavi sonrası klinik ve laboratuvar bulguları düzeldi. Sonuç olarak, özellikle hemodiyalize giren hastalarda nadirde olsa Gram-negatif bakterilerden Citrobacter freundii’nin de kateterle ilişkili kan dolaşımı enfeksiyonu etkeni olabileceği akılda tutulmalıdır.
- 23 March 2021
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 2 (1) , 25-27
İlk doz kolistin kullanımı sonrasında kolistine bağlı olarak nöropati gelişen bir olgu
Kateter enfeksiyonlarının en sık etkeni cilt florasında yer alan stafilokoklar ve diğer Gram-pozitif bakterilerdir. Citrobacter freundii çoğunlukla nozokomiyal enfeksiyon etkeni olup, nadiren kateterle ilişkili kan dolaşımı enfeksiyonuna neden olur. Bu yazıda, hemodiyalize giren 39 yaşında bir erkek hastada Citrobacter freundii’ye bağlı olarak gelişen kateterle kan dolaşımı enfeksiyonu gelişen bir olgu sunuldu. Hastanın periferik kan ve kateter içinden alınan kan örneklerinde Citrobacter freundii üredi. Hastaya 10 gün süreyle seftriakson tedavisi uygulandı, tedavi sonrası klinik ve laboratuvar bulguları düzeldi. Sonuç olarak, özellikle hemodiyalize giren hastalarda nadirde olsa Gram-negatif bakterilerden Citrobacter freundii’nin de kateterle ilişkili kan dolaşımı enfeksiyonu etkeni olabileceği akılda tutulmalıdır.
- 18 December 2020
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 1 (4) , 113-115
Bir hemodiyaliz hastasında Citrobacter freundii’ye bağlı gelişen kateter ilişkili kan dolaşım yolu enfeksiyonu
Kateter enfeksiyonlarının en sık etkeni cilt florasında yer alan stafilokoklar ve diğer Gram-pozitif bakterilerdir. Citrobacter freundii çoğunlukla nozokomiyal enfeksiyon etkeni olup, nadiren kateterle ilişkili kan dolaşımı enfeksiyonuna neden olur. Bu yazıda, hemodiyalize giren 39 yaşında bir erkek hastada Citrobacter freundii’ye bağlı olarak gelişen kateterle kan dolaşımı enfeksiyonu gelişen bir olgu sunuldu. Hastanın periferik kan ve kateter içinden alınan kan örneklerinde Citrobacter freundii üredi. Hastaya 10 gün süreyle seftriakson tedavisi uygulandı, tedavi sonrası klinik ve laboratuvar bulguları düzeldi. Sonuç olarak, özellikle hemodiyalize giren hastalarda nadirde olsa Gram-negatif bakterilerden Citrobacter freundii’nin de kateterle ilişkili kan dolaşımnı enfeksiyonu etkeni olabileceği akılda tutulmalıdır.
- 18 December 2020
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 1 (4) , 113-115
Bir hemodiyaliz hastasında Citrobacter freundii’ye bağlı gelişen kateter ilişkili kan dolaşım yolu enfeksiyonu
Kateter enfeksiyonlarının en sık etkeni cilt florasında yer alan stafilokoklar ve diğer Gram-pozitif bakterilerdir. Citrobacter freundii çoğunlukla nozokomiyal enfeksiyon etkeni olup, nadiren kateterle ilişkili kan dolaşımı enfeksiyonuna neden olur. Bu yazıda, hemodiyalize giren 39 yaşında bir erkek hastada Citrobacter freundii’ye bağlı olarak gelişen kateterle kan dolaşımı enfeksiyonu gelişen bir olgu sunuldu. Hastanın periferik kan ve kateter içinden alınan kan örneklerinde Citrobacter freundii üredi. Hastaya 10 gün süreyle seftriakson tedavisi uygulandı, tedavi sonrası klinik ve laboratuvar bulguları düzeldi. Sonuç olarak, özellikle hemodiyalize giren hastalarda nadirde olsa Gram-negatif bakterilerden Citrobacter freundii’nin de kateterle ilişkili kan dolaşımnı enfeksiyonu etkeni olabileceği akılda tutulmalıdır.